Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trametinib in Relapsed or Refractory Juvenile Myelomonocytic Leukemia
NCT03190915Phase 2Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Sep 2018
- Primary completion
- Mar 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of trametinib in juvenile myelomonocytic leukemia (JMML), sponsored by National Cancer Institute. Primary endpoint: Objective Response. Started Sep 2018; status: active, not recruiting.
02
Drugs
trametinib
03
Conditions
juvenile myelomonocytic leukemia (JMML)
Beyond the preview
Go deeper on NCT03190915.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03190915.